FibroBiologics Inc. (NASDAQ: FBLG) announced that Nasdaq confirmed the company has demonstrated compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. The biotechnology company met the $2.5 million stockholders' equity requirement and the $1.00 bid price requirement.

The Houston-based company resolved its Nasdaq compliance issues but will remain subject to one-year monitoring periods for both stockholders' equity and bid price compliance. FibroBiologics' common stock will continue to be listed and trade on Nasdaq under the symbol "FBLG."

FibroBiologics describes itself as a clinical-stage biotechnology company developing treatments for chronic diseases using fibroblast cells and fibroblast-derived materials. The company states it holds 270+ U.S. and international issued patents and patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer.

The information was disclosed in a company press release.